Wednesday, March 18, 2026 Please be aware that GA.3 (AGITG-AG0315OG): A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) trial has permanently closed. The letter of permanent trial closure/termination can be found in the members' area of the CCTG webpage under "Toolbox-Reports-Trial Closure" here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure The purpose of this study is to compare the usual approach alone to using zanidatamab plus the usual approach. The addition of zanidatamab to the usual approach could shrink cancer. But, it could also cause side effects.This study will help the study doctors find out if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if adding zanidatamab to the usual approach reduces the risk of cancer getting worse by at least 37% compared to the usual approach.Primary Publication:Pavlakis, Nick;Shitara, Kohei;Sjoquist, Katrin;Martin, Andrew;Jaworski, Anthony;Tebbutt, Niall;Bang, Yung-Jue;Alcindor, Thierry;O'Callaghan, Chris;Strickland, Andrew;Young Rha, Sun;Lee, Keun-Wook;Kim, Jin-Soo;Bai, Li-Yuan;Hara, Hiroki;Oh, Do-Youn;Yip, Sonia;Zalcberg, John;Price, Tim;Simes, John;Goldstein, David INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer (ONLINE) Journal of Clinical Oncology Journal of Clinical Oncology:ONLINE, 2024 For more information please visit the CCTG GA4 members trial page, or clinicaltrials.gov NCT06043427
